Assistant Professor, Department of Diagnostic Radiology, Department of Physics and Atmospheric Science, Department of Microbiology & Immunology, School of Biomedical Engineering
My lab focuses on the use of molecular imaging to evaluate novel drugs and improve their translation into clinical care; and to develop novel prognostic and diagnostic biomarkers that can be used in preclinical and/or clinical environments. Research in the lab ranges from development of novel acquisition techniques and analysis tools for molecular imaging to studying and testing novel cancer therapeutics in preclinical models.
As the scientific lead of the Biomedical MRI Research Lab (BMRL), a core lab in the Biomedical Translational Imaging Centre (BIOTIC; www.bioticimaging.ca), I am interested in using a wide range of molecular imaging tools to improve translation of novel therapies from the bench to the bedside. My research is highly interdisciplinary crossing several fields and departments. Located in the IWK Health Centre, the infrastructure in the BMRL includes preclinical MRI, PET/CT, SPECT and PET/MRI. Students interested in interdisciplinary research projects, particularly in the areas of imaging of cancer therapies, developing imaging and analysis tools for cell tracking, and multi-modality PET/MRI imaging should contact me about ongoing research opportunities.
|Using PET/MRI & MRI Cell Tracking for Improved Combination of Cancer Immunotherapies: This project uses novel MRI pulse sequences to allow both qualitative and quantitative monitoring of iron-labeled immune cell populations important for cancer immunotherapies. The goal is to evaluate this in a number of immune cell types and cancer models to evaluate and develop methodologies for improving combination of multiple cancer therapies.|
|Development of Novel MRI Cell Tracking Techniques: This project involves improving the use of image compression and mathematical modeling to improve and optimize MRI pulse sequences being used for cell quantification in vivo. We are also interested in developing novel MRI sequences that can allow acquisition of more quantitative information about cell populations and the tissue environment.|
|Development of Preclinical PET/MRI Technologies: Although PET/MRI has been present at some clinical sites for several years, preclinical PET/MRI is still very new. As one of flagship sites for testing this novel technology, we’re interested in exploring new methodologies and applications for this multi-modality technology.|
|KD Brewer, DR DeBay, I Dude, C Davis, K Lake, C Parsons, R Rajagopalan, G Weir, MM Stanford, M Mansour, CV Bowen. “Using Lymph Node Swelling as a Potential Biomarker for Successful Vaccination. Molecular Therapy.” Oncotarget. Accepted (2016).|
|D Debay, KD Brewer, S Leblanc, G Weir, M Stanford, M Mansour, C Bowen. “Using MRI to Evaluate and Predict Therapeutic Success from Depot-based Cancer Vaccines.” Molecular Therapy - Methods & Clinical Development. Dec 16;2:15048. (2015).|
|AJ Shuhendler*, D Ye*, KD Brewer*, M Bazalova-Carter, KH Lee, P Kempen, K Wittrup, E Graves, B Rutt, J Rao. “Molecular Magnetic Resonance Imaging of Tumor Response to Therapy.” Scientific Reports 5:14759 (2015). *Equal contributions.|
|KD Brewer, K Lake, N Pelot, M Stanford, DR Debay, A Penwell, G Weir, M Karkada, M Mansour, CV Bowen, “Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI.” Vaccine 32:6956-6962. (2014).|
|D Ye, AJ Shuhendler, P Pandit, KD Brewer, SS Tee, L Cui, G Tikhomirov, B Rutt, J Rao, “Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis.” Chemical Science 5: 3845-3852. (2014).|
|KD Brewer, JA Rioux, CV Bowen, S Beyea. “Signal Displacement in Spiral-In Acquisitions: Simulations and Implications for Imaging in SFG Regions.” Magnetic Resonance Imaging 30: 753-763. (2012).|
|JA Rioux, KD Brewer, SD Beyea, CV Bowen. “Quantification of Superparamagnetic Iron Oxide with Large Dynamic Range using TurboSPI.” Journal of Magnetic Resonance 216:152-160. (2012).|